Gene therapySensorion raised €60M backed by €20M from Sanofi to advance gene therapies for hearing lossFrench biotech company Sensorion announced today a €60 million (about $72 million) reserved offering including a €20 million strategic investment from Sanofi. The remaining €40 million subscribed … more ➔
Boehringer IngelheimBoehringer IngelheimChina again: Boehringer turns to Shanghai for IBD bispecificBoehringer Ingelheim is continuing its international shopping tour for innovative drug candidates – and once again ends up in China. The German pharmaceutical group has entered into a licensing and … more ➔
Olga Yastremska, New Africa, freepikRecombinasesDresden biotech Seamless lands up to $1.1B Eli Lilly deal for gene therapy hearing lossDresden-based experts in sequence-precise gene repair, Seamless Therapeutics, have secured a heavyweight partner. The company has entered into a global research collaboration with the world’s largest … more ➔
MarketFrom cell therapy to combat rifles: Genenta bets its future on becoming Italy’s national-security dealmakerFew biotech pivots are as jarring as Genenta’s latest move. more ➔ The Milan-based company, which went public in late 2021 on the promise of a novel cell-based gene therapy platform, is now effectively … more ➔
FundraisingUK and US venture firm Epidarex Capital announced first close fund of $145M to build life sciences start-upsThe transatlantic venture firm Epidarex Capital has reached a first close of more than $145 million (approximately €121.6 million) to focus on company creation and early-stage investments across the … more ➔
Photo of Sangharsh Lohakare from Unsplash Investment StrategyAfter decades in biotech, Gimv draws a line under new life sciences dealsBelgian investment company Gimv is drawing a clear line under one chapter of its history. The firm announced via a press release that it will stop making new investments in life sciences and instead … more ➔
ABA AustriaViennaFor €170 million: Vienna gives AI and life sciences a new homeAt a strategy retreat of the city’s political leadership, the governing parties of the City of Vienna agreed to build a new Life Science Center for Vienna – with the new AI institute AITHYRA as its … more ➔
Genmab - Photo Credit: Andrei JackametsClinical trial Genmab pauses enrollment in early ADC trial acquired from ProfoundBioGenmab has stopped enrolling patients in an early-stage clinical trial for an experimental cancer drug it gained through the acquisition of ProfoundBio in April 2024 for €1.52 billion. This pause underscores … more ➔
StatisticsUK retains Europe’s top biotech VC spot despite 2025 slowdownUK biotech is heading into 2026 with a growing sense of momentum, even as the sector continues to navigate one of the most selective investment climates in years. more ➔
LicensingLondon-based Ellipses licenses another oncologic asset from Chinese pharmaThe U.K. biotech Ellipses Pharma, which develops cancer therapeutics, announced a collaboration and licensing agreement with China-based Innolake Biopharm Co. Ltd to develop a clinical-stage, first-in-class … more ➔
Boehringer Ingelheim
Olga Yastremska, New Africa, freepik
Photo of Sangharsh Lohakare from Unsplash 
ABA Austria
Genmab - Photo Credit: Andrei Jackamets
